diethylene glycol monoethyl ether Cas:111-90-0

We are diethylene glycol monoethyl ether CAS:111-90-0 manufacturer and supplier in China, Pls send inquiry of to of visit our official website should you have any interests

diethylene glycol monoethyl ether

diethylene glycol monoethyl ether
Diethylene Glycol Monoethyl Ether
Ethanol, 2-(2-ethoxyethoxy)-
2-(2-Ethoxyethoxy)ethanol,CARBITOL™,Diethylene glycol ethyl ether
diethylene glycol ethyl ether

molecular formula: C6H14O3
Molecular weight: 134.17400
Physical Properties:
Appearance and properties: colorless liquid
Density: 0.999 g/mL at 25 °C(lit.)
Boiling point: 202 °C(lit.) Melting point: -80 °C
Flash point: 205 °F
Refractive index: n20/D 1.427(lit.)

Appearance:Colorless transparent liquid
Purity:≥99.0 %
Moisture:≤0.1 %
Distillation Range:198.0-205.0℃

Rosin can dissolve oils, insect oil, paraffin, dyes, camphor and natural resins such as resin, rosin, emulsifiable concentrate, sandalwood and other natural resins and the same kind of synthetic resin, cobe resin, paint solvent, used in the manufacture of components, composition, fast drying pigments, fast drying adhesive for enamel products. Auxiliary carriers, resins, ecological dyes and pigments. Also used are automotive auxiliaries, auxiliaries, additives, auxiliaries and auxiliaries, additives, glass pigments, etc. for coatings such as glass. Additives, additives, etc. of additives such as cleaning agents and polyaromatic hydrocarbons.
Package and Storage:
200kg/iron drum

Market News:The booster campaign, with shots administered by health maintenance organisations, will effectively turn Israel into a testing ground for a third dose before approval by the U.S. Food and Drug Administration (FDA). N-cyclohexylcyclohexanamine,(2S)-3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid manufacturer.RELATED: With Takhzyro durability data, Takeda tries to fend off BioCryst’s hereditary angioedema challenger Orladeyo 8-chloro-3-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine supplier.So, the company’s latest announcement is wonderful news,” according to the California Institute for Regenerative Medicine, or CIRM, which helped fund development of the treatment.
“This means that UCLA will now be able to begin the process of applying to the Food and Drug Administration for permission to start an expanded use protocol to treat patients,” CIRM CEO Maria Millan said in a May 28 statement.
UCLA scientist Donald Kohn, who developed the therapy, told the Los Angeles Times that he will start the FDA process for compassionate use as soon as possible. UCLA and UCL will also seek a new commercial partner, Kohn said.
Coyle replaced former CEO Kevin King, who was with the company for nine years, having previously worked for Medtronic as the executive vice president and president of the cardiovascular portfolio. Coyle said shortly after taking over that his international experience with Medtronic will help iRhythm as the company expands into new markets.
However, Coyle’s brief tenure was defined by the Medicare pricing saga with Novitas Solutions, a Medicare Administrative Contractor.
After CMS did not set a national price for long-term cardiac monitoring last December, the decision for price-setting was then passed on to the MACs.
Novitas originally posted rates for extended cardiac monitoring between $40-$50 in late January, well below the historical $311 range.
The drastically cut rates shook industry and Wall Street analysts, and the company’s stock price dropped by nearly 33% the day of the announcement.
During his first earnings call in February, Coyle said that iRhythm met with Novitas to talk about different pricing methodologies. However, Coyle was unable to say when, or if, any changes would be made.
The pricing challenges created uncertainty for a market that Wall Street analysts were consistently bullish on amid a trend of growing wearables use.
The space even saw a flurry of deals where nearly all of iRhythm’s competition was bought up by large medtechs like Philips and Boston Scientific.
Novitas ultimately set rates for shorter-term and longer-term cardiac monitoring at $103 and $115 in April, respectively, approximately one-third of historical rates.
Coyle said on a company call that the new rates were below the costs to provide the services and higher rates would need to be set, either through another Novitas adjustment or, once again, trying to get national pricing through CMS.
Throughout the Novitas saga, iRhythm’s stock price dropped from $252.65 Jan. 29 to $62 when the market opened Wednesday.
iRhythm said Coyle’s decision to resign will not impact the reimbursement strategy going forward — the company will still pursue higher rates through Novitas, other MACs and CMS.
Analysts were surprised by Coyle’s resignation.
Truist Securities analysts wrote that during a call with iRhythm management following the announcement, the company “made clear multiple times in our conversation that there have not been any notable developments since its earnings call (which was held in early May) related to reimbursement. S-chloro-N-phenylisothiocarbamoyl chloride producer.

Related Products
Product Name
2,3,5,6-Tetrafluoro-1,4-benzenedimethanol View Details
R-tetrahydropapaverine HCl Cas:54417-53-7 View Details
Epidermal Growth Factor View Details
1,5,7-Triazabicyclo[4.4.0]dec-5-ene Cas:5807-14-7 manufacturer 4-Nitro-2,3-lutidine-N-oxide manufacturer 2-Bromo-4′-chloroacetophenone manufacturer S-(Trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate Cas:129946-88-9 manufacturer 2-Methylthio-4,6-pyrimidinedione manufacturer